|
Outcome
|
GnRH agonist
|
Dienogest
|
P-value
|
|---|
|
Total dose of FSH (IU)a
|
2047 ± 67.7
|
2180 ± 57.4
|
0.65
|
|
No. of oocytea
|
11.4 ± 1.2
|
11.1 ± 1.4
|
0.78
|
|
No. of mature oocytesa
|
6.6 ± 1.3
|
6 ± 1.8
|
0.71
|
|
Fertilization rate (%) b
|
40.3%
|
47.67%
|
0.38
|
|
No. of transferrable embryosa
|
4.5 ± 1.8
|
5.1 ± 2.1
|
0.63
|
|
Transferred embryo b
|
|
Cleavage stage
|
37 (55.22%)
|
42 (62.69%)
|
0.37
|
|
Blastocyst stage
|
30 (44.78%)
|
25 (37.31%)
|
|
Pregnancy rate (%) b
|
15/67 (22.39%)
|
1 7/67 (25.37%)
|
0.69
|
|
Clinical pregnancy rate (%) b
|
12/67 (17.91%)
|
17/67 (25.37%)
|
0.29
|
|
Miscarriage rate (%) b
|
2/15 (13.3%)
|
0
|
–
|
|
Cost of pretreatment /ovarian stimulation (EGP)a
|
3664 ± 45.1
|
2773 ± 38.1
|
< 0.001
|
- EGP Egyptian Pounds, GnRHa Gonadotropin-releasing hormone agonist, FSH Follicle-stimulating Hormone
- aValues are expressed as means ± standard deviations
- bValues expressed as numbers and percentages
